Quantcast

Latest IT-101 Stories

2012-06-22 06:14:58

There are more than 42 thousand new diagnosed cases of pancreatic cancer in the U.S., and of those, more than 35 thousand have resulted in death. Now researchers are looking at a new treatment that could change how we view pancreatic cancer.

2011-01-19 16:00:00

PITTSBURGH, Jan. 19, 2011 /PRNewswire/ -- Precision Therapeutics, Inc. will present pancreatic cancer data based on Precision's ChemoFx® in-vitro chemosensitivity test at the 2011 American Society of Clinical Oncology (ASCO) GI Symposium, January 20-22 in San Francisco, California.

2010-09-15 07:00:00

LONDON and NEW YORK, Sept. 15 /PRNewswire/ -- Spirogen Limited (the "Company") and Celtic Therapeutics Holdings LP ("Celtic Therapeutics") announced today the commencement of a Phase II clinical trial of SG2000 in ovarian cancer.

2008-11-03 09:00:40

Calando Pharmaceuticals, Inc., a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR), announced today that its CEO, Dr. James Hamilton, will present at the 19th Annual Oppenheimer Healthcare Conference on Tuesday, November 4, 2008 at 11:00am ET.

2008-10-24 09:00:07

Calando Pharmaceuticals, a majority-owned subsidiary of Arrowhead Research, has completed the IT-101 Phase I clinical study conducted at City of Hope in Duarte, California. The company expects the entire study data to be published in early 2009.

2008-10-23 09:00:10

Calando Pharmaceuticals, a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR), announced today completion of the IT-101 Phase I clinical study conducted at City of Hope in Duarte, California. The company expects the entire study data to be published in early 2009.

2008-10-21 09:00:12

Arrowhead Research Corporation (NASDAQ: ARWR) announced today that the Company's CEO has provided an update letter to stockholders on its majority owned subsidiary, Calando Pharmaceuticals: Dear Arrowhead Stockholders, Calando Pharmaceuticals is Arrowhead's most mature biopharmaceutical subsidiary.

2008-09-15 09:00:58

Calando Pharmaceuticals, a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR), announced today that pre-clinical development of a second siRNA oncology therapeutic, CALAA-02, is underway. The intracellular target for CALAA-02 is HIF-2alpha, or Hypoxia Inducible Factor-2 alpha.

2008-09-12 09:00:09

Calando Pharmaceuticals, a majority owned subsidiary of Arrowhead Research, has started a Phase II clinical trial in the US evaluating the safety and efficacy of its drug candidate, IT-101, in patients with platinum-sensitive ovarian cancer. The study is open for enrollment.

2008-09-11 09:00:48

Calando Pharmaceuticals, Inc., a majority owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR), announced today that it has initiated a Phase II clinical trial in the United States evaluating the safety and efficacy of its drug candidate, IT-101 in patients with platinum-sensitive ovarian cancer.


Word of the Day
bretelles
  • In dressmaking, straps running from the belt in front over the shoulders to the belt in the back, with more or less elaboration of trimming and outline. They usually broaden at the shoulder and narrow toward the waist.
The word 'bretelles' comes from a French word meaning 'braces'.